Table 3.

Clinical and biochemical profiles of DNP, diabetic control and healthy control groups

	DNP n=10	Diabetic controls n=7	Healthy controls of DNP n=8
Gender (F/M)	5/5	4/3	4/4
Age, mean ± SD (years)	50.10±6.05*§	51.00±6.30*	48.13±7.22§	*p=0.770 §p=0.536
Duration of diabetes, median (years)	5.0	4.0	-	p=0.588
Serum glucose, mean ± SD (mg/dl)	152.20±43.77*§	146.14±51.73*	95.13±4.82§	*p=0.660 §p=0.003
HbA1 c%, median	6.65	6.20	-	p=0.525
SMMT, mean ± SD	28.60±2.01*§	28.71±1.11*	29.50±0.76§	*p=0.610 §p=0.332
Oral antidiabetic use	7/10	4/7	-	p=0.644
Insulin use	1/10	2/7	-	p=0.537
CMAP amplitude, median (mV)	6.40	8.30 (5 out of 7 patients)	-	p=0.297

p values in bold represent statistical significance.

DNP, painful diabetic neuropathy; SMMT, standardized mini-mental test; CMAP, compound muscle action potential; SD, standard deviation; F, female M, male